About Entellus Medical (ENTL)
Entellus Medical, Inc. is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment. The Company's XprESS Multi-Sinus Dilation family of products consists of its XprESS Pro device, its XprESS LoProfile device and its XprESS Ultra device. The MiniFESS family of surgical instruments includes eight devices designed to enable physicians to perform various surgical procedures. The Fiagon Image Guidance System (IGS) consists of a navigation unit, navigation sensor, software instruments and a patient localizer.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Instruments & Supplies
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: ENTL
- CUSIP: N/A
- Previous Close: $14.22
- 50 Day Moving Average: $13.79
- 200 Day Moving Average: $16.93
- 52-Week Range: $12.31 - $22.63
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -18.23
- P/E Growth: -0.57
- Market Cap: $311.09M
- Outstanding Shares: 21,877,000
- Beta: 0.26
- Net Margins: -36.91%
- Return on Equity: -53.20%
- Return on Assets: -32.44%
- Debt-to-Equity Ratio: 0.33%
- Current Ratio: 2.78%
- Quick Ratio: 2.50%
Companies Related to Entellus Medical:
Earnings History for Entellus Medical (NASDAQ:ENTL)Earnings History by Quarter for Entellus Medical (NASDAQ:ENTL)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/2/2017|| || || || || || || || |
|2/21/2017||Q4 2016||($0.33)||($0.39)||$21.58 million||$21.70 million||View||Listen|
|11/3/2016||Q3||($0.37)||($0.50)||$17.93 million||$17.90 million||View||Listen|
|8/3/2016||Q2||($0.35)||($0.27)||$18.48 million||$18.73 million||View||Listen|
|5/4/2016||Q1||($0.47)||($0.37)||$16.34 million||$16.90 million||View||Listen|
|2/24/2016||Q4||($0.26)||($0.27)||$17.52 million||$18.07 million||View||Listen|
|11/5/2015||Q315||($0.25)||($0.32)||$14.19 million||$14.80 million||View||Listen|
|8/6/2015||Q215||($0.20)||($0.15)||$15.00 million||$15.20 million||View||Listen|
Earnings Estimates for Entellus Medical (NASDAQ:ENTL)
2017 EPS Consensus Estimate: ($1.19)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Entellus Medical (NASDAQ:ENTL)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Entellus Medical (NASDAQ:ENTL)
Insider Ownership Percentage: 9.10%Insider Trades by Quarter for Entellus Medical (NASDAQ:ENTL)
Institutional Ownership Percentage: 60.67%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|1/31/2017||Life Sciences Fu International||Major Shareholder||Sell||533,077||$17.00||$9,062,309.00|| |
|1/13/2017||Brian E Farley||Director||Sell||14,019||$20.14||$282,342.66|| |
|1/13/2017||Karen E. Peterson||VP||Sell||10,000||$20.13||$201,300.00|| |
|1/10/2017||Brian E Farley||Director||Sell||9,842||$19.11||$188,080.62|| |
|1/10/2017||Karen E. Peterson||VP||Sell||9,840||$19.11||$188,042.40|| |
|1/4/2017||Brian E Farley||Director||Sell||20,158||$18.74||$377,760.92|| |
|1/4/2017||Karen E Peterson||VP||Sell||10,160||$18.74||$190,398.40|| |
|12/6/2016||Brian E Farley||Director||Sell||15,000||$18.57||$278,550.00|| |
|11/23/2016||Brian E Farley||Director||Sell||5,000||$19.00||$95,000.00|| |
|11/18/2016||Brian E Farley||Director||Sell||10,000||$18.30||$183,000.00|| |
|10/13/2016||Margaret A. Boiano||VP||Sell||11,103||$20.01||$222,171.03|| |
|10/5/2016||Brian E Farley||Director||Sell||30,000||$22.26||$667,800.00|| |
|9/8/2016||James D Surek||VP||Sell||10,000||$18.71||$187,100.00|| |
|9/2/2016||Brian E Farley||Director||Sell||11,078||$18.62||$206,272.36|| |
|9/1/2016||Brian E Farley||Director||Sell||17,006||$19.33||$328,725.98|| |
|9/1/2016||Kevin L. Mensink||VP||Sell||8,000||$18.39||$147,120.00|| |
|8/1/2016||Kevin L Mensink||VP||Sell||8,100||$17.63||$142,803.00|| |
|7/18/2016||Timothy B. Petrick||VP||Sell||3,000||$18.15||$54,450.00|| |
|2/11/2016||Karen E Peterson||Insider||Sell||5,000||$16.00||$80,000.00|| |
|2/4/2016||Karen E Peterson||Insider||Sell||10,000||$17.00||$170,000.00|| |
|9/17/2015||Brian E. Farley||Chairman||Sell||5,484||$22.00||$120,648.00|| |
|9/15/2015||Brian E. Farley||Chairman||Sell||27,619||$22.18||$612,589.42|| |
|9/14/2015||Brian E. Farley||Chairman||Sell||21,187||$22.15||$469,292.05|| |
|9/2/2015||James D Surek||VP||Sell||15,000||$21.27||$319,050.00|| |
|8/31/2015||James D. Surek||VP||Sell||5,000||$22.29||$111,450.00|| |
|2/3/2015||Robert S White||COO||Buy||5,882||$17.00||$99,994.00|| |
|2/3/2015||Shawn Mccormick||Director||Buy||2,941||$17.00||$49,997.00|| |
|2/3/2015||Woodlands Health Venture Essex||Major Shareholder||Buy||352,941||$17.00||$5,999,997.00|| |
Headline Trends for Entellus Medical (NASDAQ:ENTL)
Latest Headlines for Entellus Medical (NASDAQ:ENTL)
|Entellus Medical (ENTL) Getting Favorable Media Coverage, AlphaOne Reports|
www.americanbankingnews.com - April 28 at 2:00 PM
|Entellus Medical Inc (ENTL) Upgraded to Hold at Zacks Investment Research|
www.americanbankingnews.com - April 25 at 7:53 PM
|Entellus Medical Inc (ENTL) Short Interest Update|
www.americanbankingnews.com - April 24 at 5:54 PM
|Entellus Medical, Inc. – Value Analysis (NASDAQ:ENTL) : April 24, 2017|
finance.yahoo.com - April 24 at 4:49 PM
|Entellus Medical (ENTL) Earns Daily Coverage Optimism Rating of 0.12|
www.americanbankingnews.com - April 24 at 10:44 AM
|Entellus Medical (ENTL) Earning Somewhat Favorable Press Coverage, AlphaOne Reports|
www.americanbankingnews.com - April 21 at 2:40 PM
|Entellus Medical, Inc. breached its 50 day moving average in a Bullish Manner : ENTL-US : April 21, 2017|
finance.yahoo.com - April 21 at 11:59 AM
|Entellus Medical to Present at the Deutsche Bank Annual Health Care Conference|
finance.yahoo.com - April 20 at 5:06 PM
|Entellus Medical to Report First Quarter 2017...|
www.benzinga.com - April 19 at 9:57 PM
|Entellus Medical to Report First Quarter 2017 Financial Results on May 3, 2017|
finance.yahoo.com - April 19 at 9:57 PM
|Entellus Medical (ENTL) Getting Favorable Media Coverage, Report Shows|
www.americanbankingnews.com - April 18 at 4:06 PM
|Entellus Medical (ENTL) Given Daily News Impact Score of 0.28|
www.americanbankingnews.com - April 15 at 9:45 AM
|$19.47 Million in Sales Expected for Entellus Medical Inc (ENTL) This Quarter|
www.americanbankingnews.com - April 13 at 11:31 AM
|Canaccord Genuity Reiterates Buy Rating for Entellus Medical Inc (ENTL)|
www.americanbankingnews.com - April 12 at 9:32 PM
|Entellus Medical Receives FDA 510(k) Clearance for Eustachian Tube Indication|
finance.yahoo.com - April 12 at 5:01 PM
|Entellus Medical Inc (ENTL) Expected to Post Earnings of -$0.43 Per Share|
www.americanbankingnews.com - April 11 at 6:07 PM
|Entellus Medical Inc (ENTL) Receives Average Rating of "Hold" from Analysts|
www.americanbankingnews.com - April 7 at 9:05 PM
|ETFs with exposure to Entellus Medical, Inc. : April 5, 2017|
finance.yahoo.com - April 7 at 9:38 AM
|Entellus Medical, Inc. (ENTL)|
finance.yahoo.com - March 29 at 11:34 AM
|Entellus Medical Inc (ENTL) Sees Significant Growth in Short Interest|
www.americanbankingnews.com - March 28 at 8:08 AM
|ENTELLUS MEDICAL INC Financials|
finance.yahoo.com - February 28 at 5:09 PM
|Q4 2016 Entellus Medical Inc Earnings Release - After Market Close|
us.rd.yahoo.com - February 23 at 3:20 AM
|ENTELLUS MEDICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi|
us.rd.yahoo.com - February 23 at 3:19 AM
|ENTELLUS MEDICAL INC Files SEC form 10-K, Annual Report|
biz.yahoo.com - February 22 at 10:18 PM
|Moving Average Crossover Alert: Entellus Medical (ENTL)|
www.zacks.com - February 22 at 7:56 AM
|Entellus Medical Announces Fourth Quarter and Full Year 2016 Financial Results|
finance.yahoo.com - February 22 at 7:56 AM
|Entellus Medical to Report Fourth Quarter and Full Year 2016 Financial Results on February 21, 2017|
finance.yahoo.com - February 1 at 5:34 PM
|Entellus Medical (ENTL) Commences $60M Offering of Common Stock|
www.streetinsider.com - January 26 at 6:20 PM
|ENTELLUS MEDICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financial State|
us.rd.yahoo.com - January 25 at 11:20 PM
|Entellus Medical Announces Pricing of Public Offering of Common Stock|
finance.yahoo.com - January 25 at 11:20 PM
|Entellus Medical Announces Proposed Public Offering of Common Stock|
www.nasdaq.com - January 25 at 6:18 PM
|ENTELLUS MEDICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors or Princi|
biz.yahoo.com - January 5 at 5:49 PM
|National Institute for Health and Care Excellence (NICE) Provides Positive Guidance for Use of the XprESS Multi-Sinus Dilation System for Treating Chronic Sinusitis|
us.rd.yahoo.com - December 13 at 10:40 PM
|9:30 am Entellus Medical announces that the National Institute for Health and Care Excellence Medical Technologies Advisory Committee provided positive guidance for use of the XprESS Multi-Sinus Dilation System for the treatment of chronic |
us.rd.yahoo.com - December 13 at 10:40 PM
|National Institute for Health and Care Excellence (NICE) Provides Positive Guidance for Use of the|
www.nasdaq.com - December 13 at 11:31 AM
|Coverage initiated on Entellus Medical by Guggenheim|
us.rd.yahoo.com - December 8 at 1:37 AM
|Entellus Medical Announces Publication of Positive Clinical Data for XprESS for Treatment of Pediatric Chronic Rhinosinusitis|
finance.yahoo.com - November 29 at 5:31 PM
|8:53 am Entellus Medical announces results of a prospective, multicenter clinical study using its XprESS balloon sinus dilation system in pediatric patients were published in the peer reviewed journal International Forum of Allergy & Rhinol|
finance.yahoo.com - November 29 at 5:31 PM
|Edited Transcript of ENTL earnings conference call or presentation 3-Nov-16 8:30pm GMT|
finance.yahoo.com - November 22 at 4:34 PM
|Entellus Medical to Present at the Piper Jaffray Healthcare Conference|
finance.yahoo.com - November 16 at 4:58 PM
|Coverage initiated on Entellus Medical by Deutsche Bank|
finance.yahoo.com - October 6 at 4:48 PM
|ENTELLUS MEDICAL INC Files SEC form 10-Q/A, Quarterly Report|
biz.yahoo.com - August 4 at 10:36 PM
Frequently Asked Questions for Entellus Medical (NASDAQ:ENTL)
What is Entellus Medical's stock symbol?
Entellus Medical trades on the NASDAQ under the ticker symbol "ENTL."
How were Entellus Medical's earnings last quarter?
Entellus Medical Inc (NASDAQ:ENTL) announced its quarterly earnings results on Tuesday, February, 21st. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.33) by $0.06. The firm earned $21.70 million during the quarter, compared to analysts' expectations of $21.58 million. Entellus Medical had a negative net margin of 36.91% and a negative return on equity of 53.20%. The firm's revenue for the quarter was up 20.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.27) EPS.
When will Entellus Medical make its next earnings announcement?
Entellus Medical is scheduled to release their next quarterly earnings announcement on Tuesday, May, 2nd 2017.
What guidance has Entellus Medical issued on next quarter's earnings?
Entellus Medical issued an update on its FY15 earnings guidance on Thursday, August, 6th. The company provided earnings per share guidance of ($1.10-0.80) for the period, compared to the Thomson Reuters consensus estimate of ($0.98). The company issued revenue guidance of $58.5-61 million, compared to the consensus revenue estimate of $60.31 million.Entellus Medical also updated its Q3 guidance to ($0.20-0.28) EPS.
Where is Entellus Medical's stock going? Where will Entellus Medical's stock price be in 2017?
6 brokerages have issued 1-year price objectives for Entellus Medical's shares. Their forecasts range from $16.00 to $26.00. On average, they expect Entellus Medical's stock price to reach $22.80 in the next twelve months.
What are analysts saying about Entellus Medical stock?
Here are some recent quotes from research analysts about Entellus Medical stock:
- 1. According to Zacks Investment Research, "Entellus Medical, Inc. is a medical technology company. It is engaged in the designing, development and commercialization of products for the treatment of chronic sinusitis. The company operates primarily in the United States and Canada. Entellus Medical, Inc. is headquartered in Plymouth, Minnesota. " (4/25/2017)
- 2. Canaccord Genuity analysts commented, "We maintain our BUY rating following marketing meetings with management. We recently hosted Entellus Medical’s management team for a day of investor meetings in Boston. We traveled with Bob White, President and CEO and Brent Moen, CFO. Meetings were largely positive as procedural growth (both office based and OR) and reimbursement changes remain a focus for investors. We came away from those meetings with a clearer understanding of reimbursement changes, broader product portfolio, and OUS growth potential. Net, net we remain positive about Entellus’ growth opportunities despite investor uncertainty on the reimbursement front headed into 2017. Near term, as management noted on the Q3/16 conference call, we expect Entellus will set conservative guidance for 2017 to the low end of the historic 20%-25% range, and as such, set the potential for a beat and raise cadence over the H2/17. We expect reimbursement will be at the forefront of investor minds moving into 2017 as the industry digests 30-50% cuts to reimbursement in the hospital outpatient setting." (12/20/2016)
Are investors shorting Entellus Medical?
Entellus Medical saw a increase in short interest in the month of March. As of March 31st, there was short interest totalling 1,229,555 shares, an increase of 16.5% from the March 15th total of 1,055,120 shares. Based on an average daily trading volume, of 122,330 shares, the days-to-cover ratio is presently 10.1 days.
When did Entellus Medical IPO?
(ENTL) raised $70 million in an initial public offering (IPO) on Friday, January 30th 2015. The company issued 4,400,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch and Piper Jaffray served as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.
Who owns Entellus Medical stock?
Entellus Medical's stock is owned by a variety of of institutional and retail investors. Top institutional investors include
DISCOVERY GROUP I, LLC
DISCOVERY GROUP I, LLC
(6.50%) and Perkins Capital Management Inc. (0.27%). Company insiders that own Entellus Medical stock include Brian E Farley, James D Surek, Karen E Peterson, Kevin L Mensink, Life Sciences Fu International, Margaret A Boiano and Timothy B Petrick.
Who bought Entellus Medical stock? Who is buying Entellus Medical stock?
Entellus Medical's stock was acquired by a variety of institutional investors in the last quarter, including Perkins Capital Management Inc..
How do I buy Entellus Medical stock?
Shares of Entellus Medical can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Entellus Medical stock cost?
One share of Entellus Medical stock can currently be purchased for approximately $14.22.
Entellus Medical (ENTL) Chart for Saturday, April, 29, 2017